Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Abnormal host cells recognized by NK cells via stress ligands and altered MHC class I refers to a cellular state, typically found in malignant or virally infected cells, that renders them susceptible to Natural Killer (NK) cell-mediated destruction. This recognition is governed by a balance of signals: the 'missing-self' mechanism occurs when cells downregulate MHC class I to evade T-cells, which removes inhibitory signals to NK cell Killer-cell Immunoglobulin-like Receptors (KIRs) (Ljunggren & Kärre, 1990, Immunology Today). Concurrently, 'induced-self' recognition involves the upregulation of stress-induced ligands (such as MICA, MICB, and ULBPs) that bind to the activating receptor NKG2D on NK cells (Lanier, 2015, Nature Reviews Immunology). In therapeutic contexts, this axis is targeted by checkpoint inhibitors like Lirilumab (anti-KIR) and Monalizumab (anti-NKG2A) to disinhibit NK cells, or by CAR-NK cells and bispecific engagers that specifically bind to stress ligands on the abnormal cells (Vivier et al., 2011, Science; André et al., 2018, Cell). This target description represents a physiological mechanism of immune evasion and recognition rather than a single molecular entity.
Enhancement of NK cell-mediated cytotoxicity by blocking inhibitory receptors (e.g., KIR, NKG2A) or activating NK cells through stress-ligand recognition (e.g., NKG2D engagement).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Abnormal host cells recognized by NK cells via stress ligands and altered MHC class I.